ICRA Reaffirms Strong Credit Ratings for Rossari Biotech's Rs 333.31 Crore Banking Facilities

1 min read Updated on 03 Dec 2025, 07:07 PM

Reviewed by

Riya DScanX News Team

Overview

ICRA Limited has reaffirmed Rossari Biotech's credit ratings for banking facilities totaling Rs 333.31 crore. The company received ICRA[AA- (Positive)] for long-term facilities and ICRA[A1+] for short-term facilities. Rossari's financial health shows robust growth with total assets increasing by 20.61% to Rs 1,896.20 crore and current assets rising by 23.51%. This reaffirmation underscores Rossari's strong market position, financial profile, and growth in the specialty chemicals sector.

*this image is generated using AI for illustrative purposes only.

Rossari Biotech Limited , a leading specialty chemicals manufacturer, has received a vote of confidence from ICRA Limited, which has reaffirmed the company's credit ratings for its banking facilities totaling Rs 333.31 crore. This reaffirmation underscores the company's strong financial position and growth trajectory in the specialty chemicals sector.

Credit Ratings Breakdown

ICRA has maintained its ratings for Rossari Biotech's various banking facilities as follows:

Facility Type	Amount (Rs Crore)	Long-Term Rating	Short-Term Rating
Fund-Based Term Loans	60.00	ICRA[AA- (Positive)]	-
Working Capital Facilities	240.00	ICRA[AA- (Positive)]	-
Non-Fund Based Limits	23.31	-	ICRA[A1+]
Unallocated Limits	10.00	ICRA[AA- (Positive)]	ICRA[A1+]
Total	333.31

The 'AA-' rating indicates a high degree of safety regarding timely servicing of financial obligations, while the 'A1+' rating denotes the highest level of safety for short-term instruments.

Financial Performance Insights

An analysis of Rossari Biotech's consolidated balance sheet reveals robust financial health:

Metric	Amount (Rs Crore)	YoY Change
Total Assets	1,896.20	+20.61%
Shareholders' Capital	1,185.40	+13.14%
Current Assets	1,041.90	+23.51%
Fixed Assets	598.30	+3.58%

The company has demonstrated significant growth across key financial metrics, with total assets expanding by 20.61% year-over-year to Rs 1,896.20 crore. This growth is supported by a 23.51% increase in current assets, indicating improved liquidity and operational efficiency.

Strategic Implications

The reaffirmation of Rossari Biotech's credit ratings by ICRA is a testament to the company's:

Strong market position in the specialty chemicals industry
Robust financial profile with consistent growth
Prudent financial management and liquidity position
Diversified product portfolio and customer base

These ratings are likely to enhance Rossari Biotech's ability to access capital markets and negotiate favorable terms with lenders, supporting its future growth initiatives and expansion plans.

Conclusion

ICRA's reaffirmation of Rossari Biotech's credit ratings reflects the company's solid financial foundation and positive outlook. As the specialty chemicals sector continues to evolve, Rossari Biotech appears well-positioned to capitalize on market opportunities and maintain its growth trajectory. Investors and stakeholders can view this rating action as a positive indicator of the company's financial stability and future prospects.

Historical Stock Returns for Rossari Biotech

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.49%	+1.98%	-6.06%	-10.34%	-27.22%	-27.72%

Key Details of the Land Transfer

Aspect	Details
Subsidiary Company	Unitop Chemicals Private Limited
Parent Company	Rossari Biotech Limited
Land Area	Approximately 12,608 sq. mt.
Location	Dahej, Gujarat
Effective Date	November 24, 2025
Transferring Authority	Gujarat Industrial Development Corporation (GIDC)

Implications for Rossari Biotech

The transfer of land rights to Unitop Chemicals Private Limited marks a step in Rossari Biotech's expansion. This move may strengthen the subsidiary's operational capabilities in the industrial chemicals sector, potentially leading to increased production capacity and market presence.

Background

Rossari Biotech Limited, a company known for its presence in the specialty chemicals sector, has been focusing on expanding its footprint in various industrial segments. The acquisition of land rights by its material subsidiary aligns with this strategy, indicating the company's efforts to enhance its manufacturing capabilities.

Conclusion

This land rights transfer represents a development for Rossari Biotech and its subsidiary, Unitop Chemicals. As the industrial chemicals sector continues to evolve, such expansions could play a role in maintaining competitiveness and driving growth in the market.

Historical Stock Returns for Rossari Biotech